Matthew Stephen Wake,Anaïs Palin,Audrey Belot,Mathieu Berger,Megane Lorgouilloux,Margot Bichon,Jonathan Papworth,Luke Thomas Bayliss,Ben Grimshaw,Natalie Rynkiewicz,Jemima Paterson,Alicia Poindron,Erin Spearing,Emily Carter,Robyne Hudson,Millie Campbell,Verena Petzer,Céline Besson-Fournier,Chloé Latour,Amélie Largounez,Ophélie Goubeyre,Alexis Fay,Helene Coppin,Marie-Paule Roth,Igor Theurl,Volker Germaschewski,Delphine Meynard

Abstract:Iron plays a major role in the deterioration of β-thalassemia. Indeed, the high levels of transferrin saturation and iron delivered to erythroid progenitors are associated with production of α-globin precipitates that negatively affect erythropoiesis. Matriptase-2/TMPRSS6, a membrane-bound serine protease expressed in hepatocytes, negatively modulates hepcidin production and thus is a key target to prevent iron overload in β-thalassemia. To address safety concerns raised by the suppression of Tmprss6 by anti-sense oligonucleotides or small interfering RNA, we tested a fully human anti-matriptase-2 antibody, RLYB331, that blocks the protease activity of matriptase-2. When administered weekly to Hbb th3/+ mice, RLYB331 induced hepcidin expression, reduced iron loading, prevented the formation of toxic α-chain/heme aggregates, reduced ROS formation, and improved reticulocytosis and splenomegaly. To increase the effectiveness of RLYB331 in β-thalassemia treatment even further, we administered RLYB331 in combination with RAP-536L, a ligand-trapping protein that contains the extracellular domain of activin receptor type IIB and alleviates anemia by promoting differentiation of late-stage erythroid precursors. RAP-536L alone did not prevent iron overload but significantly reduced apoptosis in the erythroid populations of the bone marrow, normalized red blood cell counts and improved hemoglobin and hematocrit levels. Interestingly, the association of RLYB331 with RAP-536L entirely reversed the β-thalassemia phenotype in Hbb th3/+ mice and simultaneously corrected iron overload, ineffective erythropoiesis, splenomegaly and hematological parameters, suggesting that a multi-functional molecule consisting of the fusion of RLYB331 with Luspatercept (human version of RAP-536L) would allow administration of a single medication addressing simultaneously the different pathophysiological aspects of β-thalassemia.

TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis

Genetic analysis of TMPRSS6 catalytic domain variants in Mexican patients with iron treatment refractoriness

An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia

Effect of TMPRSS6 rs855791 (T>C) polymorphism on pathophysiology of iron-deficiency anemia

Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators: a systematic review with meta-analyses

TMPRSS6 cleaves KCNE1 and causes arrhythmias in iron overload disease

TMPRSS6, but Not TF, TFR2 or BMP2 Variants Are Associated with Increased Risk of Iron-Deficiency Anemia.

A Strong Anti-Inflammatory Signature Revealed by Liver Transcription Profiling of Tmprss6−/− Mice

A single approach to targeting transferrin receptor 2 corrects iron and erythropoietic defects in murine models of anemia of inflammation and chronic kidney disease

Novel missense mutation in the TMPRSS6 gene in a Japanese female with iron-refractory iron deficiency anemia

Combination of a TGF‐β ligand trap (RAP‐GRL) and TMPRSS6‐ASO is superior for correcting β‐thalassemia

Rational In Silico Design of Selective TMPRSS6 Peptidomimetic Inhibitors via Exploitation of the S2 Subpocket

Heme-Regulated Eif2 Alpha Kinase (Hri) Is Required For Translational Regulation And Survival Of Erythroid Precursors In Iron Deficiency

Transmembrane serine protease 6, a novel target for inhibition of neuronal tumor growth

Pharmacophore-based computational study on inhibitor of TMPRSS6 as hepcidin modulator in an iron overload of beta-thalassaemia

The association of TMPRSS6 gene polymorphism with iron status in Egyptian children (a pilot study)

Association of TMPRSS6 polymorphisms with ferritin, hemoglobin, and type 2 diabetes risk in a Chinese Han population.

Extrahepatic deficiency of transferrin receptor 2 is associated with increased erythropoiesis independent of iron overload

Iron metabolism and iron disorders revisited in the hepcidin era

SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia

A human Anti-matriptase-2 antibody limits iron overload, α-globin aggregates and splenomegaly in β-thalassemic mice